216 related articles for article (PubMed ID: 22726541)
1. Proteasome inhibitors: introduction.
Heuck CJ; Shaughnessy JD
Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
[No Abstract] [Full Text] [Related]
2. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
4. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Hideshima T; Anderson KC
Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
[TBL] [Abstract][Full Text] [Related]
5. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
6. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
7. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in proteasome inhibitor-based cancer therapies.
Dou QP
Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
[No Abstract] [Full Text] [Related]
9. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
10. The proteasome in terminal plasma cell differentiation.
Cenci S
Semin Hematol; 2012 Jul; 49(3):215-22. PubMed ID: 22726544
[TBL] [Abstract][Full Text] [Related]
11. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
Manasanch EE; Korde N; Zingone A; Tageja N; Fernandez de Larrea C; Bhutani M; Wu P; Roschewski M; Landgren O
Leuk Lymphoma; 2014 Aug; 55(8):1707-14. PubMed ID: 24261677
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacology of proteasome inhibitors.
Rentsch A; Landsberg D; Brodmann T; Bülow L; Girbig AK; Kalesse M
Angew Chem Int Ed Engl; 2013 May; 52(21):5450-88. PubMed ID: 23526565
[TBL] [Abstract][Full Text] [Related]
13. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
15. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
18. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
19. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N; Ling SC
J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
